Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49.6M
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
6.67M
-
Shares change
-
-277K
-
Total reported value, excl. options
-
$34M
-
Value change
-
-$1.72M
-
Number of buys
-
11
-
Number of sells
-
-7
-
Price
-
$5.08
Significant Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q1 2022
23 filings reported holding CADL - Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q1 2022.
Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 6.67M shares
of 49.6M outstanding shares and own 13.45% of the company stock.
Largest 10 shareholders include FMR LLC (1.97M shares), Northpond Ventures, LLC (1.94M shares), FRANKLIN RESOURCES INC (1.13M shares), Sands Capital Ventures, LLC (812K shares), VANGUARD GROUP INC (407K shares), BlackRock Inc. (132K shares), GEODE CAPITAL MANAGEMENT, LLC (75.2K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (75K shares), 683 Capital Management, LLC (40.9K shares), and STATE STREET CORP (27.6K shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.